Vyvgart Iv MG denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for vyvgart iv mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Vyvgart (efgartigimod alfa) IV

Quantity limit denials for Vyvgart IV occur when the prescribed dosing schedule, number of cycles, or total treatment duration exceeds what UnitedHealthcare's coverage policy considers standard for the approved indication. UHC typically defines an approved treatment course based on the FDA-approved prescribing information. Denials arise when a prescriber orders additional cycles, a modified schedule for clinical reasons, or a higher-than-standard frequency.

## Why This Denial Is Appealable

Quantity limit policies must reflect the FDA-approved label and recognized clinical practice. If your physician has clinical justification for the prescribed quantity — such as documented disease recurrence, incomplete response, or a patient-specific factor affecting treatment frequency — that justification can form the basis of a compelling appeal.

## Your Federal Appeal Rights

• Internal appeal: File under ACA §2719 / ERISA §503. Submit within the deadline on your denial notice. UHC must review and respond within statutory timeframes (30 days pre-service, 60 days post-service).
• External review: If internal appeal fails, request IRO review under ACA §2719 external review. You generally have up to approximately four months from the final internal denial.
• Expedited review: Request this track if delay would seriously jeopardize your neurological function or health.

## Documentation to Gather

1. Prescriber justification letter: The neurologist should explain in clinical terms why the prescribed quantity is medically necessary for this patient — referencing the FDA label's dosing guidance and the patient's specific clinical course. 2. Treatment response record: Chart documentation of the patient's response (or partial response) to prior cycles, including validated functional assessments before and after each treatment cycle. 3. Disease activity documentation: Any evidence of relapse, worsening, or clinical instability that supports the need for the prescribed schedule. 4. FDA label reference: Attach the relevant section of the FDA-approved prescribing information showing the dosing regimen, so the reviewer can compare what was prescribed against what is approved.

## Criteria-Mapping Structure

Obtain UHC's quantity limit policy for efgartigimod IV. List each quantity limit criterion and map it to chart evidence. If the prescribed quantity exceeds the default limit, the physician's letter must explain the clinical exception and cite the applicable professional society guideline organization (without quoting specific numbers) to show this is recognized practice.

## Practical Note

If the denial is purely administrative (e.g., a billing code error inflated the apparent quantity), a corrected claim may resolve it faster than a formal appeal. Confirm the submitted quantity matches the actual prescription before escalating.